SOHM, Inc., Updates, Revises Its short-term and Long-term Goals.
CHINO HILLS, CA / June 29, 2022 / SOHM, Inc. (OTC PINK: SHMN), a Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, released more information today regarding its long-awaited short-term and long-term goals
Mr. Baron Night, President and CEO of the SOHM, Inc., is pleased to inform its stakeholders of activities the company has undertaken within Q1 and Q2 of the 2022 year.
SOHM, Inc., has signed agreements with various ANDA holders to license products under the SOHM private label for distribution in the United States. New products include Colsevelam Hydrochloride, used to lower high cholesterol levels in the blood. Topiramate, an anticonvulsant drug used in the control of epilepsy and in the prophylaxis and treatment of migraines, and Salsalate, is used to help treat the pain of osteoarthritis or rheumatoid arthritis. The company expects the revenues of newly added products to begin Q4 of 2022.
The company has noted that due to the current geopolitical climate, supply chain instability and growing inflation coupled with foreign exchange fluctuations within the continent of Africa, Brainwise™ revenues are expected to reduce to two hundred and fifty thousand dollars for the 2022 year.
Mr. Night, CEO stated, that despite the downsizing of Brainwise™ projections, the company expects to increase its current revenues by 50% to 75% due to the expansion of daily use prescription and nonprescription offerings under the SOHM Brand private label. “Under the current circumstances of the global economy, SOHM is working tirelessly to ensure that American consumers retain accessibility to the medications that promote their physical, emotional, and mental well-being.”
When speaking on the pending acquisition of a southern California-based pharmaceutical company, Mr. Baron Night, President and CEO of the SOHM, Inc., said, that “while we have signed a definitive agreement to acquire the Southern California-based pharmaceutical license company, the due diligence is still under process and has been slowed down delays that are out of our control” While the definitive agreement is valid and in place until the of the year, SOHM., Inc has taken the decision to set up its own pharmaceutical facility based in Southern California simultaneously. “Our team is auditing and identifying facilities in the Southern California region that would house the various formats of pharmaceutical products we intend to produce and promote with the “Made in America” label.
The company intends to have the following segments manufactured at their facility.
Topicals, SOLID Dose, Oral liquids, both Pharmaceutical and Nutraceutical. Currently, SOHM Inc. is producing its regular topical prescription products at its partner contract manufacturing facilities within the region while hoping to finalize its facility by the end of Q3.
“We look forward to welcoming our new partners and to building on our combined expertise in pharmaceutical manufacturing, stated Mr. Night. “We are incredibly proud of what our Company has accomplished and look forward to the next chapter.”
About SOHM, Inc.: SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that tries to build continuous growth. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India and a strategic alliance with US manufacturing facilities. Although SOHM’s generic pharmaceuticals were exported globally and introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To learn more about SOHM, Inc., visit www.SOHM.com
Safe Harbor Statement:
This news release contains “forward-looking statements”, which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.
For more information, please contact: